BioSpace News Archive

jCyte, Inc. today announced the expansion of the role of Dr. Samir Mody. In addition to his Chief Commercial Officer responsibilities focused on preparing for the North American launch of jCell, Dr. Mody will now also assume leadership for the Global Pricing, Health Economics, and Reimbursement functions for jCyte.

Lunaphore today announced it will host a virtual scientific talk in partnership with Labroots on October 21, 2021, about spatial “omics” methods as a laboratory service.

TG Therapeutics, Inc. today announced data presentations, including additional analyses from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide, in patients with relapsing forms of multiple sclerosis (RMS).

A new report published by FirstWord Therapy Trends presents a comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer (NSCLC) market, emphasizing current and future treatment pathways.

Todos Medical announced today that its Chief Scientific Officer, Dr. Jorge Leone, and Sean Taylor, North American FAS Manager of GenScript, will conduct a webinar discussing the importance of the cPass™ SARS-COV-2

Predictmedix Inc. today announced that its Form 20-F registration statement, voluntary filed with the United States Securities and Exchange Commission on June 17, 2021, has cleared all comments from the SEC.

Imbed Biosciences, Inc. (Imbed) announced today that it has been awarded $800,000 in a Commercialization Readiness Pilot (CRP) grant by the National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to support late-stage development of a next-generation wound dressing that can kill bacteria hidden inside the biofilms in wounds and accelerate wound healing.

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its third quarter 2021 results after market close on Tuesday, November 2, 2021, to be followed by a conference call at 5:00 p.m. (Eastern Time).

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI’s Catalyst Day on Monday, October 18, 2021.

Moderna, Inc. (Nasdaq: MRNA), today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for a booster dose of the Moderna COVID-19 vaccine (mRNA-1273) at the 50 µg dose level for people aged 65 and older.